Block listing Interim Review
1 June 2021 15:01 BST
BLOCK LISTING SIX MONTHLY RETURN
Information provided on this form must be typed or printed electronically and provided to an ris.
(Note: Italicised terms have the same meaning as given in the Listing Rules.)
Date: 1 June 2021
|Name of applicant:||ASTRAZENECA PLC|
|Name of scheme:||ASTRAZENECA SHARE OPTION PLAN; ASTRAZENECA SAVINGS-RELATED SHARE OPTION PLAN; ASTRAZENECA ALL-EMPLOYEE SHARE PLAN; ASTRAZENECA PLC 2012 SAVINGS-RELATED SHARE OPTION SCHEME|
|Period of return:||From:||1 DECEMBER 2020||To:||31 MAY 2021|
|Balance of unallotted securities under scheme(s) from previous return:||709,452|
|Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):||5,000,000|
|Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):||456,674|
|Equals: Balance under scheme(s) not yet issued/allotted at end of period:||5,252,778|
|Name of contact:||HANNAH TATTERSALL|
|Telephone number of contact:||+44 (0)746 498 2582|
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines in Oncology and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries, and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact firstname.lastname@example.org or visit www.rns.com.